Navigation Links
FDA Approves Blood Thinner Brilinta for Heart Patients
Date:7/20/2011

WEDNESDAY, July 20 (HealthDay News) -- In a long-awaited move, the U.S. Food and Drug Administration late Wednesday approved the blood thinner Brilinta (ticagrelor) for use in patients with acute coronary syndromes, to help lower their odds for heart attack and death.

Acute coronary syndromes include common conditions such as unstable angina or heart attack linked to lowered blood flow to the heart, the FDA noted in a statement. Brilinta, developed by pharmaceutical giant AstraZeneca, works to prevent new blood clots from forming.

The agency's move comes after a number of studies found that Brilinta performed well against the standard blood thinner now in use, Plavix (clopidogrel).

"In clinical trials, Brilinta was more effective than Plavix in preventing heart attacks and death, but that advantage was seen with aspirin maintenance doses of 75 to 100 milligrams once daily," Dr. Norman Stockbridge, director of the Division of Cardiovascular and Renal Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

In approving Brilinta, the FDA is mandating a "boxed warning" on the drug's labeling, advising that taking the drug along with daily aspirin doses above 100 milligrams could decrease its effectiveness. The FDA is also mandating that AstraZeneca "conduct educational outreach to physicians to alert them about the risk of using higher doses of aspirin."

The boxed warning will also note that, as can happen with blood thinners generally, Brilinta may raise the odds for bleeding. According to the FDA, the most common side effects seen with Brilinta were bleeding and/or shortness of breath.

Late last month, a study presented at an American Heart Association press conference found that heart patients who took Brilinta with low-dose aspirin (less than 300 milligrams) had fewer cardiovascular complications than those taking Plavix plus low-dose aspirin. But, as the FDA noted in its approval, that benefit vanished when higher doses of aspirin were used.

Speaking at the time, Dr. Jeffrey S. Berger, assistant professor of medicine and director of cardiovascular thrombosis at NYU Langone Medical Center in New York City, said that "the study highlights that if one chooses to use ticagrelor in subjects with acute coronary syndromes, it would be logical to use aspirin 81 milligrams per day (and not 325 mg daily)."

He added that, "there is little reason to ever use aspirin 325 mg except in the acute setting of a heart attack or stroke. A higher aspirin dose (325 mg versus 81 mg) increases the risk of bleeding without increasing the efficacy of the drug."

More information

Find out more about preventing heart attack at the U.S. National Heart, Lung, and Blood Institute.

-- HealthDay Staff

SOURCES: U.S. Food and Drug Administration, news release, July 20, 2011; Jeffrey S. Berger, M.D., assistant professor, medicine and director, cardiovascular thrombosis, NYU Langone Medical Center, New York City


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Approves Test That Spots Aggressive Breast Cancer
2. FDA Approves Test That Spots HER2-Positive Breast Cancers
3. FDA Approves Another New Drug to Fight Hepatitis C
4. FDA approves new drug for advanced melanoma
5. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
6. FDA Approves 1st New Lupus Drug in More Than 50 Years
7. FDA Approves First 3D Mammogram Device
8. FDA Approves First Pacemaker Deemed Safe During MRIs
9. FDA Approves First Drug to Prevent Premature Births
10. Swiss agency approves clinical trial of UCI-created neural stem cell therapy
11. ACGME board approves final duty hour and supervision standards for resident education
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves Blood Thinner Brilinta for Heart Patients
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology: